Last Updated on September 1, 2026 by Dr. Bhagat
Immunity’s 2025 Journal Impact Factor is 30.6, according to the Journal Citation Reports data released in 2026. The Cell Press journal is listed in the Immunology category, indexed in SCIE, and placed in Q1. This page combines the current JIF with publisher-reported journal metrics, publication options and practical submission guidance.
2026 data update
Journal Impact Factor year: 2025 · JCR release year: 2026 · Current JIF: 30.6 · Quartile: Q1
Immunity journal metrics at a glance
| Metric | Current value |
| 2025 Journal Impact Factor | 30.6 |
| Five-year Journal Impact Factor | 32.3 |
| JCR category | Immunology |
| JCR quartile | Q1 |
| Web of Science edition | Science Citation Index Expanded (SCIE) |
| CiteScore | 44.9 |
| Time to first editorial decision | 7 days |
| Acceptance to online publication | 27 days |
| Publishing model | Subscription or open access |
| Print ISSN | 1074-7613 |
| Electronic ISSN | 1097-4180 |
Metric note: the current JIF and CiteScore are displayed by Elsevier on the official Immunity journal pages. The five-year JIF, category, quartile and SCIE coverage correspond to the current JCR record. Publisher metrics can change, so authors should recheck the official pages before making a submission decision.
About Immunity
Immunity is a monthly, peer-reviewed journal published by Cell Press, an Elsevier imprint. It began publication in 1994 and covers important advances across the discipline of immunology. The journal’s scope includes immune-cell development and function, innate and adaptive immunity, inflammation, infection, autoimmunity, allergy, transplantation, cancer immunology and interactions between immune processes and other biological systems.
The journal prioritizes work that provides a substantial conceptual or mechanistic advance. A technically sound study may still be unsuitable if the result is narrow, mainly descriptive or unlikely to interest Immunity’s broad research audience. Authors should therefore evaluate editorial fit alongside citation metrics.
What is Immunity’s Impact Factor in 2025?
Immunity’s Journal Impact Factor for 2025 is 30.6. The figure belongs to the citation year 2025 and appears in the Journal Citation Reports release issued in 2026. Therefore, “2025 Impact Factor” and “JCR 2026” describe the same reporting cycle rather than two different metrics.
The Journal Impact Factor measures citations received during the JCR year by eligible content published in the preceding two years, divided by the number of citable items from those years. It is a journal-level citation indicator—not a score for every article, author or research project.
Is Immunity a Q1 and SCIE-indexed journal?
Yes. Immunity is listed in the Immunology category, placed in Q1, and covered by the Science Citation Index Expanded (SCIE). Q1 indicates placement in the highest quartile of journals within the relevant JCR category. The journal is also indexed in MEDLINE and PubMed from volume 1, according to the National Library of Medicine catalog.
Immunity Impact Factor history, 2017–2025
| Impact Factor year | Impact Factor | Year-on-year change |
|---|---|---|
| 2017 | 19.734 | — |
| 2018 | 21.522 | +9.1% |
| 2019 | 22.553 | +4.8% |
| 2020 | 31.745 | +40.8% |
| 2021 | 43.474 | +36.9% |
| 2022 | 32.4 | −25.5% |
| 2023 | 25.5 | −21.3% |
| 2024 | 26.3 | +3.1% |
| 2025 | 30.6 | +16.3% |
The series rose strongly in 2020 and 2021, declined in 2022 and 2023, and then increased for two consecutive years. The latest change is from 26.3 in 2024 to 30.6 in 2025, an increase of approximately 16.3%. This table describes the numerical record only and does not assign a cause to annual movements.
Research scope and suitable manuscripts
Immunity publishes research that advances understanding of immune mechanisms and their biological or clinical relevance. Common areas include lymphocyte biology, myeloid-cell function, antigen presentation, immune signaling, mucosal and barrier immunity, host–pathogen interactions, immunometabolism, autoimmunity, allergy, tumor immunology, vaccines and systems-level analysis of immune responses.
A strong submission normally does more than apply a fashionable method or describe a new dataset. Authors should be able to explain the central biological principle, the evidence supporting the mechanism, and why the result matters to readers beyond one narrow experimental system.
Article types published by Immunity
The journal publishes original research and editorial content for a broad immunology audience. Its author guidance includes research articles and review-based formats. Reviews are generally commissioned or discussed with the editors and are intended to provide a comprehensive, authoritative treatment of a topic.
- Research articles: substantial original studies with conceptual and mechanistic importance.
- Reviews: broad, authoritative syntheses of timely areas in immunology.
- Perspectives and related editorial formats: forward-looking analysis, discussion and community context, subject to the journal’s current specifications.
Because format names, limits and commissioning policies can change, authors should use the live Cell Press article-types page rather than relying on old third-party instructions.
Immunity review and publication times
Elsevier currently reports a median of 7 days to the first editorial decision. This is the initial editorial-stage metric and should not be interpreted as the duration of complete external peer review. Papers sent to referees will usually take longer, and revision time depends on the work requested and the authors’ response.
The journal also reports a median of 27 days from acceptance to online publication. This post does not publish an unofficial acceptance rate or promise a total review duration because the publisher does not provide a single dependable figure that applies to every manuscript type.
Is Immunity open access?
Immunity is a hybrid journal. Authors can choose the subscription route or pay for immediate open-access publication. Cell Press states that there is no publication fee for the standard subscription option. Under the open-access route, the final article is made openly available under the applicable licence.
The current journal page lists an open-access article publishing charge of US$10,400, excluding taxes. Charges, waiver rules, institutional agreements and funder arrangements can change, so authors should confirm the amount directly with Cell Press before budgeting.
Submission and reporting checklist
- Explain the main conceptual advance and why it matters across immunology.
- Confirm that the manuscript fits the journal’s current scope and article type.
- For initial submission, follow the live Cell Press instructions for PDF or Word-file preparation.
- Prepare transparent methods, statistical details, data availability and code availability where relevant.
- Follow Cell Press STAR Methods and key-resources requirements when requested for the article type.
- Disclose related manuscripts, competing interests, funding and required ethical approvals.
- Check figure, source-data and reporting requirements before the revision stage.
- Choose the subscription or open-access route after checking funder and institutional requirements.
Publisher, frequency and identifiers
| Journal title | Immunity |
| Publisher | Cell Press, an Elsevier imprint |
| Publication start | 1994 |
| Frequency | Monthly |
| Print ISSN | 1074-7613 |
| Electronic ISSN | 1097-4180 |
| NLM title abbreviation | Immunity |
| MEDLINE coverage | Indexed from volume 1 |
How to interpret Immunity’s metrics responsibly
A JIF of 30.6 and CiteScore of 44.9 indicate high journal-level citation activity, but they do not predict the impact or quality of an individual paper. Citation distributions are uneven, fields cite at different rates, and review articles can behave differently from original research.
For a submission decision, combine the metrics with scope, editorial expectations, readership, publishing model, research transparency, cost and the needs of the intended audience. The best journal is the one that fits the study and reaches the right readers—not simply the title with the largest number.
Frequently asked questions
What is Immunity’s 2025 Impact Factor?
Immunity’s 2025 Journal Impact Factor is 30.6 in the 2026 JCR release.
What is Immunity’s five-year Impact Factor?
The current five-year Journal Impact Factor is 32.3.
Is Immunity a Q1 journal?
Yes. Immunity is in Q1 in the Immunology category.
Is Immunity indexed in SCIE and MEDLINE?
Yes. Immunity is covered by SCIE and is indexed in MEDLINE and PubMed from its first volume.
What is Immunity’s CiteScore?
Elsevier currently displays a CiteScore of 44.9.
How quickly does Immunity make an initial decision?
The journal reports a median of 7 days to the first editorial decision. This is not the complete external peer-review time.
Does Immunity publish an acceptance rate?
No dependable current acceptance percentage is publicly reported by the publisher, so this page does not present an estimate as fact.
What is the open-access fee?
Cell Press currently lists an open-access publishing charge of US$10,400 excluding taxes. The subscription route has no publication fee.
Sources and data notes
- Immunity: official Elsevier journal metrics
- Immunity: official information for authors
- Immunity: official publishing options
- Immunity: official article types
- NLM Catalog: Immunity
- Clarivate Journal Citation Reports
Data checked: 1 September 2026. Current publisher metrics, fees and operational figures can change. Authors should verify time-sensitive information on the official journal pages before submitting.
